Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINFOTARGAM: R-CHOP/14 + HAART in HIV-Associated DLBCL
NCT00466258Phase 4Completed
- Sponsor
- Fundación PETHEMA
- Start
- Oct 2006
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Fundación PETHEMA. Primary endpoints: Treatment toxicity according to CTC criteria at 6 months, Opportunistic and non-opportunistic infections rate at 6 months and 1 more. Started Oct 2006; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00466258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00466258.